JP2021532118A - 質量分析のための試薬 - Google Patents
質量分析のための試薬 Download PDFInfo
- Publication number
- JP2021532118A JP2021532118A JP2021503727A JP2021503727A JP2021532118A JP 2021532118 A JP2021532118 A JP 2021532118A JP 2021503727 A JP2021503727 A JP 2021503727A JP 2021503727 A JP2021503727 A JP 2021503727A JP 2021532118 A JP2021532118 A JP 2021532118A
- Authority
- JP
- Japan
- Prior art keywords
- unit
- group
- reactive
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004949 mass spectrometry Methods 0.000 title abstract description 71
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 57
- 239000012491 analyte Substances 0.000 claims abstract description 293
- 238000000034 method Methods 0.000 claims abstract description 102
- 238000005259 measurement Methods 0.000 claims abstract description 27
- 230000007935 neutral effect Effects 0.000 claims description 237
- 150000001875 compounds Chemical class 0.000 claims description 202
- -1 N-hydroxysuccinimide (NHS) ester Chemical class 0.000 claims description 151
- 150000002500 ions Chemical class 0.000 claims description 125
- 238000006243 chemical reaction Methods 0.000 claims description 65
- 125000005842 heteroatom Chemical group 0.000 claims description 61
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 52
- 238000013467 fragmentation Methods 0.000 claims description 45
- 238000006062 fragmentation reaction Methods 0.000 claims description 45
- 230000008569 process Effects 0.000 claims description 40
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 38
- 125000004432 carbon atom Chemical group C* 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 238000004458 analytical method Methods 0.000 claims description 25
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 22
- 150000003536 tetrazoles Chemical group 0.000 claims description 22
- 238000004611 spectroscopical analysis Methods 0.000 claims description 20
- 125000004185 ester group Chemical group 0.000 claims description 19
- 125000003386 piperidinyl group Chemical group 0.000 claims description 14
- 150000003852 triazoles Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 10
- 150000004662 dithiols Chemical group 0.000 claims description 8
- PCGDBWLKAYKBTN-UHFFFAOYSA-N 1,2-dithiole Chemical compound C1SSC=C1 PCGDBWLKAYKBTN-UHFFFAOYSA-N 0.000 claims description 5
- IVJFXSLMUSQZMC-UHFFFAOYSA-N 1,3-dithiole Chemical group C1SC=CS1 IVJFXSLMUSQZMC-UHFFFAOYSA-N 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 177
- 229910052739 hydrogen Inorganic materials 0.000 description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- 239000000523 sample Substances 0.000 description 76
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 54
- 239000000047 product Substances 0.000 description 49
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 48
- 125000000524 functional group Chemical group 0.000 description 44
- 238000004811 liquid chromatography Methods 0.000 description 38
- 239000011324 bead Substances 0.000 description 35
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 29
- 229960003604 testosterone Drugs 0.000 description 29
- 230000015572 biosynthetic process Effects 0.000 description 27
- 238000004128 high performance liquid chromatography Methods 0.000 description 27
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 26
- 230000005291 magnetic effect Effects 0.000 description 26
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 25
- 239000002904 solvent Substances 0.000 description 25
- 125000003277 amino group Chemical group 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- 125000000468 ketone group Chemical group 0.000 description 22
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 21
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 21
- 150000002118 epoxides Chemical group 0.000 description 19
- 239000002243 precursor Substances 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical group C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 18
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 18
- 125000003172 aldehyde group Chemical group 0.000 description 18
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000000087 stabilizing effect Effects 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 125000002897 diene group Chemical group 0.000 description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- HTJMXYRLEDBSLT-UHFFFAOYSA-N 1,2,4,5-tetrazine Chemical group C1=NN=CN=N1 HTJMXYRLEDBSLT-UHFFFAOYSA-N 0.000 description 16
- OKJCFMUGMSVJBG-ABEVXSGRSA-N Delta(1)-dihydrotestosterone Chemical class C1C(=O)C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OKJCFMUGMSVJBG-ABEVXSGRSA-N 0.000 description 16
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 16
- 239000002253 acid Substances 0.000 description 16
- 150000003338 secosteroids Chemical class 0.000 description 16
- 125000003368 amide group Chemical group 0.000 description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 15
- 125000002228 disulfide group Chemical group 0.000 description 15
- 238000011534 incubation Methods 0.000 description 15
- 125000003396 thiol group Chemical group [H]S* 0.000 description 15
- 238000001514 detection method Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 14
- 239000002207 metabolite Substances 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 150000003431 steroids Chemical class 0.000 description 14
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical group C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 13
- 150000002009 diols Chemical group 0.000 description 13
- 229960005309 estradiol Drugs 0.000 description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 description 13
- 125000004430 oxygen atom Chemical group O* 0.000 description 13
- 238000002953 preparative HPLC Methods 0.000 description 13
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 12
- 230000005526 G1 to G0 transition Effects 0.000 description 12
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 12
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 12
- 238000010828 elution Methods 0.000 description 12
- 229960002061 ergocalciferol Drugs 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 125000005843 halogen group Chemical group 0.000 description 12
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 12
- 235000001892 vitamin D2 Nutrition 0.000 description 12
- 239000011653 vitamin D2 Substances 0.000 description 12
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 12
- 235000005282 vitamin D3 Nutrition 0.000 description 12
- 239000011647 vitamin D3 Substances 0.000 description 12
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 12
- 229940021056 vitamin d3 Drugs 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 150000001720 carbohydrates Chemical class 0.000 description 10
- 238000010494 dissociation reaction Methods 0.000 description 10
- 230000005593 dissociations Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000001228 spectrum Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 9
- 150000000180 1,2-diols Chemical class 0.000 description 9
- SWINWPBPEKHUOD-UHFFFAOYSA-N 2-hydroxyestron Natural products OC1=C(O)C=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 SWINWPBPEKHUOD-UHFFFAOYSA-N 0.000 description 9
- LUEYUHCBBXWTQT-UHFFFAOYSA-N 4-phenyl-2h-triazole Chemical compound C1=NNN=C1C1=CC=CC=C1 LUEYUHCBBXWTQT-UHFFFAOYSA-N 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- 125000004036 acetal group Chemical group 0.000 description 9
- 150000001299 aldehydes Chemical class 0.000 description 9
- 150000001345 alkine derivatives Chemical class 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000004140 cleaning Methods 0.000 description 9
- 238000001360 collision-induced dissociation Methods 0.000 description 9
- 238000001212 derivatisation Methods 0.000 description 9
- 150000002016 disaccharides Chemical class 0.000 description 9
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 9
- 229960001348 estriol Drugs 0.000 description 9
- 229960002870 gabapentin Drugs 0.000 description 9
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 9
- 229960005277 gemcitabine Drugs 0.000 description 9
- 125000000879 imine group Chemical group 0.000 description 9
- 229960005181 morphine Drugs 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 9
- 230000003637 steroidlike Effects 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000004807 desolvation Methods 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 210000003296 saliva Anatomy 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- PDRGHUMCVRDZLQ-UHFFFAOYSA-N d-equilenin Natural products OC1=CC=C2C(CCC3(C4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-UHFFFAOYSA-N 0.000 description 7
- 238000000132 electrospray ionisation Methods 0.000 description 7
- PDRGHUMCVRDZLQ-WMZOPIPTSA-N equilenin Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-WMZOPIPTSA-N 0.000 description 7
- 229930182833 estradiol Natural products 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000004817 gas chromatography Methods 0.000 description 7
- 230000002949 hemolytic effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 6
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 6
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 6
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 6
- IICQXOJPUDICND-UHFFFAOYSA-N 1,2,4-triazole-3,5-dione Chemical compound O=C1NC(=O)N=N1 IICQXOJPUDICND-UHFFFAOYSA-N 0.000 description 6
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 6
- PROQIPRRNZUXQM-LMMHAMTPSA-N 16,17-epiestriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H]([C@@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-LMMHAMTPSA-N 0.000 description 6
- KJDGFQJCHFJTRH-YONAWACDSA-N 16-Ketoestradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](C(=O)C4)O)[C@@H]4[C@@H]3CCC2=C1 KJDGFQJCHFJTRH-YONAWACDSA-N 0.000 description 6
- KJDGFQJCHFJTRH-UHFFFAOYSA-N 16-Ketoestradiol Natural products OC1=CC=C2C3CCC(C)(C(C(=O)C4)O)C4C3CCC2=C1 KJDGFQJCHFJTRH-UHFFFAOYSA-N 0.000 description 6
- FRVHJVATKMIOPQ-PAPWGAKMSA-N 17-Methyl-5-alpha-androst-2-en-17-beta-ol Chemical compound C([C@@H]1CC2)C=CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 FRVHJVATKMIOPQ-PAPWGAKMSA-N 0.000 description 6
- PROQIPRRNZUXQM-PNVOZDDCSA-N 17-epiestriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-PNVOZDDCSA-N 0.000 description 6
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 6
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 6
- YBCPNMOFBUWYTP-UHFFFAOYSA-N 2-Hydroxyestron-3-methylether Natural products C1CC2C3CCC(=O)C3(C)CCC2C2=C1C=C(OC)C(O)=C2 YBCPNMOFBUWYTP-UHFFFAOYSA-N 0.000 description 6
- WHEUWNKSCXYKBU-UHFFFAOYSA-N 2-Methoxyestron Natural products C12CCC3(C)C(=O)CCC3C2CCC2=C1C=C(OC)C(O)=C2 WHEUWNKSCXYKBU-UHFFFAOYSA-N 0.000 description 6
- SWINWPBPEKHUOD-JPVZDGGYSA-N 2-hydroxyestrone Chemical compound OC1=C(O)C=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 SWINWPBPEKHUOD-JPVZDGGYSA-N 0.000 description 6
- IECMOFZIMWVOAS-UHFFFAOYSA-N 4,4-dimethylpiperidine Chemical compound CC1(C)CCNCC1 IECMOFZIMWVOAS-UHFFFAOYSA-N 0.000 description 6
- JSACPXBJRYHNHN-UHFFFAOYSA-N 4-[4-(6-methoxy-1,3-benzoxazol-2-yl)phenyl]-1,2,4-triazole-3,5-dione Chemical group O1C2=CC(OC)=CC=C2N=C1C(C=C1)=CC=C1N1C(=O)N=NC1=O JSACPXBJRYHNHN-UHFFFAOYSA-N 0.000 description 6
- BCWZIZLVBYHFES-PYEWSWHRSA-N 4-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=CC(O)=C1OC BCWZIZLVBYHFES-PYEWSWHRSA-N 0.000 description 6
- MEJAPGGFIJZHEJ-UHFFFAOYSA-N 5-acetamido-1,3,4-thiadiazole-2-sulfonyl chloride Chemical group CC(=O)NC1=NN=C(S(Cl)(=O)=O)S1 MEJAPGGFIJZHEJ-UHFFFAOYSA-N 0.000 description 6
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 6
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- KZFBHCCLJSAHBQ-UHFFFAOYSA-N Benzoylecgonine Natural products CN1C2CCC1C(C(C2)OC(=C)c3ccccc3)C(=O)O KZFBHCCLJSAHBQ-UHFFFAOYSA-N 0.000 description 6
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 6
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 6
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 6
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 6
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 6
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 6
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 229960002478 aldosterone Drugs 0.000 description 6
- 229960004821 amikacin Drugs 0.000 description 6
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 6
- 229940025084 amphetamine Drugs 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- 150000001540 azides Chemical class 0.000 description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- 229960005084 calcitriol Drugs 0.000 description 6
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 6
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 6
- 125000002843 carboxylic acid group Chemical group 0.000 description 6
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 6
- 229960002438 carfilzomib Drugs 0.000 description 6
- 108010021331 carfilzomib Proteins 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 6
- 229960000928 clofarabine Drugs 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 6
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 6
- 229960002433 cysteine Drugs 0.000 description 6
- 229960000684 cytarabine Drugs 0.000 description 6
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 6
- 229960002069 diamorphine Drugs 0.000 description 6
- GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 description 6
- 229960003399 estrone Drugs 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 125000001976 hemiacetal group Chemical group 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 229960004716 idoxuridine Drugs 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- 229960004194 lidocaine Drugs 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- PZXIEBDIPWIRGB-UHFFFAOYSA-N methyl 2-pyridin-3-ylacetate Chemical compound COC(=O)CC1=CC=CN=C1 PZXIEBDIPWIRGB-UHFFFAOYSA-N 0.000 description 6
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 6
- 150000002772 monosaccharides Chemical class 0.000 description 6
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 6
- 229960000951 mycophenolic acid Drugs 0.000 description 6
- 229950006780 n-acetylglucosamine Drugs 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 229960002847 prasterone Drugs 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 6
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 6
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical group C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 6
- 229960004889 salicylic acid Drugs 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 150000004044 tetrasaccharides Chemical class 0.000 description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 6
- 150000003573 thiols Chemical class 0.000 description 6
- 229960000707 tobramycin Drugs 0.000 description 6
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 6
- 229960004380 tramadol Drugs 0.000 description 6
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 6
- 150000004043 trisaccharides Chemical class 0.000 description 6
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 5
- 238000013375 chromatographic separation Methods 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 230000000171 quenching effect Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 4
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical group C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 4
- HVRBCXZGTURXBT-UHFFFAOYSA-N 2,5-dimethyltetrazole Chemical group CC=1N=NN(C)N=1 HVRBCXZGTURXBT-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930003316 Vitamin D Natural products 0.000 description 4
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 125000003636 chemical group Chemical group 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- OLXYLDUSSBULGU-UHFFFAOYSA-N methyl pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1 OLXYLDUSSBULGU-UHFFFAOYSA-N 0.000 description 4
- 238000003953 normal phase liquid chromatography Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 229940046008 vitamin d Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- JWUBBDSIWDLEOM-UEGFJKGBSA-N (1r,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@H](O)CCC1=C JWUBBDSIWDLEOM-UEGFJKGBSA-N 0.000 description 3
- KJKIIUAXZGLUND-FOZBYKFWSA-N (1r,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(e,2r,5s)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@H](O)CCC1=C KJKIIUAXZGLUND-FOZBYKFWSA-N 0.000 description 3
- FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- SFXPZLCQRZASKK-UHFFFAOYSA-N (3alpha,5alpha)-3-Hydroxypregn-16-en-20-one Natural products C1CC2CC(O)CCC2(C)C2C1C1CC=C(C(=O)C)C1(C)CC2 SFXPZLCQRZASKK-UHFFFAOYSA-N 0.000 description 3
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 3
- YKKHSYLGQXKVMO-HZPDHXFCSA-N (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid Chemical compound C([C@H]1C(C)(C)O2)C=C(C)C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O YKKHSYLGQXKVMO-HZPDHXFCSA-N 0.000 description 3
- LDSYPJSYQOUQMN-WAJSLEGFSA-N (8R,9S,13S,14S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 LDSYPJSYQOUQMN-WAJSLEGFSA-N 0.000 description 3
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- BPEQZNMKGFTMQE-LXHCYJFYSA-N (e,3r,6r)-6-[(1r,3as,4e,7ar)-4-[(2z)-2-[(5s)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-1-yl]-2,3-dimethylhept-4-ene-2,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@@](C)(O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C BPEQZNMKGFTMQE-LXHCYJFYSA-N 0.000 description 3
- LJOQGZACKSYWCH-LHHVKLHASA-N (s)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol Chemical compound C1=C(OC)C=C2C([C@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-LHHVKLHASA-N 0.000 description 3
- 0 *=CC(C*CON)=CC=[N+]Cc1c[n]nn1 Chemical compound *=CC(C*CON)=CC=[N+]Cc1c[n]nn1 0.000 description 3
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 3
- 125000000424 1,2-diol group Chemical group 0.000 description 3
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 3
- JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 3
- USWVWJSAJAEEHQ-UHFFFAOYSA-N 1,3-benzodioxolyl-n-methylbutanamine Chemical compound CCC(NC)CC1=CC=C2OCOC2=C1 USWVWJSAJAEEHQ-UHFFFAOYSA-N 0.000 description 3
- 150000000190 1,4-diols Chemical class 0.000 description 3
- VHMRXGAIDDCGDU-UHFFFAOYSA-N 1-(1',3'-benzodioxol-5'-yl)-2-butanamine Chemical compound CCC(N)CC1=CC=C2OCOC2=C1 VHMRXGAIDDCGDU-UHFFFAOYSA-N 0.000 description 3
- PVXVWWANJIWJOO-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-N-ethylpropan-2-amine Chemical compound CCNC(C)CC1=CC=C2OCOC2=C1 PVXVWWANJIWJOO-UHFFFAOYSA-N 0.000 description 3
- SFXPZLCQRZASKK-CKBUFISISA-N 1-[(3s,5s,8r,9s,10s,13s,14s)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC=C(C(=O)C)[C@@]2(C)CC1 SFXPZLCQRZASKK-CKBUFISISA-N 0.000 description 3
- BTNXVMLCKOPOEP-UHFFFAOYSA-N 1-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-4-(2-phenoxyethyl)-1,2,4-triazolidine-3,5-dione Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(O)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 BTNXVMLCKOPOEP-UHFFFAOYSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- JERGUCIJOXJXHF-UHFFFAOYSA-N 17alpha-Hydroxypregnenolone Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 JERGUCIJOXJXHF-UHFFFAOYSA-N 0.000 description 3
- JERGUCIJOXJXHF-TVWVXWENSA-N 17alpha-hydroxypregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JERGUCIJOXJXHF-TVWVXWENSA-N 0.000 description 3
- ZGLHBRQAEXKACO-XJRQOBMKSA-N 1alpha,25-dihydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C ZGLHBRQAEXKACO-XJRQOBMKSA-N 0.000 description 3
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 3
- BEQZHFIKTBVCAU-UHFFFAOYSA-N 2-amino-2-(2-chlorophenyl)-1-cyclohexanone Chemical compound C=1C=CC=C(Cl)C=1C1(N)CCCCC1=O BEQZHFIKTBVCAU-UHFFFAOYSA-N 0.000 description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- DILDHNKDVHLEQB-XSSYPUMDSA-N 2-hydroxy-17beta-estradiol Chemical compound OC1=C(O)C=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 DILDHNKDVHLEQB-XSSYPUMDSA-N 0.000 description 3
- GNXFOGHNGIVQEH-UHFFFAOYSA-N 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 3
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 3
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 3
- QYIGFZOHYGYBLX-UHFFFAOYSA-N 2-phenyl-2-sulfanylacetic acid Chemical compound OC(=O)C(S)C1=CC=CC=C1 QYIGFZOHYGYBLX-UHFFFAOYSA-N 0.000 description 3
- LCZBQMKVFQNSJR-UJPCIWJBSA-N 21-deoxycortisol Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)C[C@@H]2O LCZBQMKVFQNSJR-UJPCIWJBSA-N 0.000 description 3
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 3
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 description 3
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 description 3
- KJKIIUAXZGLUND-ICCVIKJNSA-N 25-hydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C KJKIIUAXZGLUND-ICCVIKJNSA-N 0.000 description 3
- HPMZBILYSWLILX-UMDUKNJSSA-N 3'''-O-acetyldigitoxin Chemical compound C1[C@H](OC(C)=O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O HPMZBILYSWLILX-UMDUKNJSSA-N 0.000 description 3
- NGBBVGZWCFBOGO-UHFFFAOYSA-N 3,4-Methylenedioxyamphetamine Chemical compound CC(N)CC1=CC=C2OCOC2=C1 NGBBVGZWCFBOGO-UHFFFAOYSA-N 0.000 description 3
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
- AHQUALIGAOCMNW-UHFFFAOYSA-N 4-(chloromethyl)-1-phenyltriazole Chemical compound N1=NC(CCl)=CN1C1=CC=CC=C1 AHQUALIGAOCMNW-UHFFFAOYSA-N 0.000 description 3
- KPBDDCHVARVOII-UHFFFAOYSA-N 5,5-dimethyltetrazole Chemical compound CC1(C)N=NN=N1 KPBDDCHVARVOII-UHFFFAOYSA-N 0.000 description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 3
- MARUHZGHZWCEQU-UHFFFAOYSA-N 5-phenyl-2h-tetrazole Chemical compound C1=CC=CC=C1C1=NNN=N1 MARUHZGHZWCEQU-UHFFFAOYSA-N 0.000 description 3
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 3
- JJGYGPZNTOPXGV-SSTWWWIQSA-N 6-Acetylmorphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O JJGYGPZNTOPXGV-SSTWWWIQSA-N 0.000 description 3
- HEFRPWRJTGLSSV-UHFFFAOYSA-N 7-Aminoclonazepam Chemical compound C12=CC(N)=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl HEFRPWRJTGLSSV-UHFFFAOYSA-N 0.000 description 3
- LTCDLGUFORGHGY-UHFFFAOYSA-N 7-Aminoflunitrazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(N)C=C2C=1C1=CC=CC=C1F LTCDLGUFORGHGY-UHFFFAOYSA-N 0.000 description 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HPMZBILYSWLILX-UHFFFAOYSA-N Acetyl-digitoxine Natural products C1C(OC(C)=O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O HPMZBILYSWLILX-UHFFFAOYSA-N 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- BYYMILHAKOURNM-UHFFFAOYSA-N Buturon Chemical compound C#CC(C)N(C)C(=O)NC1=CC=C(Cl)C=C1 BYYMILHAKOURNM-UHFFFAOYSA-N 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- BDSGOXYXFMSOQV-UHFFFAOYSA-N CNC(CCC)C1OC2=C(O1)C=CC=C2 Chemical compound CNC(CCC)C1OC2=C(O1)C=CC=C2 BDSGOXYXFMSOQV-UHFFFAOYSA-N 0.000 description 3
- 235000021318 Calcifediol Nutrition 0.000 description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 3
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 3
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 3
- BXBPJMHHWPXBJL-UHFFFAOYSA-N Dehydronorketamine Chemical compound C=1C=CC=C(Cl)C=1C1(N)CCC=CC1=O BXBPJMHHWPXBJL-UHFFFAOYSA-N 0.000 description 3
- YOVRGSHRZRJTLZ-UHFFFAOYSA-N Delta9-THCA Natural products C1=C(C(O)=O)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 YOVRGSHRZRJTLZ-UHFFFAOYSA-N 0.000 description 3
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 3
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 3
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 3
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 3
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 108010053070 Glutathione Disulfide Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 239000004201 L-cysteine Substances 0.000 description 3
- 235000013878 L-cysteine Nutrition 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- 239000004158 L-cystine Substances 0.000 description 3
- 235000019393 L-cystine Nutrition 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 3
- 125000003047 N-acetyl group Chemical group 0.000 description 3
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- UWJUQVWARXYRCG-HIFRSBDPSA-N O-Desmethyltramadol Chemical compound CN(C)C[C@H]1CCCC[C@]1(O)C1=CC=CC(O)=C1 UWJUQVWARXYRCG-HIFRSBDPSA-N 0.000 description 3
- GXLFYVWQXRNZON-UHFFFAOYSA-N O1N=NC(C=2C=CC=CC=2)=C1S(=O)(=O)C Chemical compound O1N=NC(C=2C=CC=CC=2)=C1S(=O)(=O)C GXLFYVWQXRNZON-UHFFFAOYSA-N 0.000 description 3
- 108010016076 Octreotide Proteins 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 3
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 3
- UCONUSSAWGCZMV-UHFFFAOYSA-N Tetrahydro-cannabinol-carbonsaeure Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCCCC)C(C(O)=O)=C2O UCONUSSAWGCZMV-UHFFFAOYSA-N 0.000 description 3
- OXHNQTSIKGHVBH-ANULTFPQSA-N Tetrahydrogestrinone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(CC)C=C2 OXHNQTSIKGHVBH-ANULTFPQSA-N 0.000 description 3
- RMMPZDDLWLALLJ-UHFFFAOYSA-N Thermophillin Chemical compound COC1=CC(=O)C(OC)=CC1=O RMMPZDDLWLALLJ-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 3
- 108010058907 Tiopronin Proteins 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 229960004308 acetylcysteine Drugs 0.000 description 3
- 229960003635 acetyldigitoxin Drugs 0.000 description 3
- 229960004150 aciclovir Drugs 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 3
- 229960003190 adenosine monophosphate Drugs 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- ZURUZYHEEMDQBU-UHFFFAOYSA-N alpha-Hydroxyalprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(CO)=NN=C2CN=C1C1=CC=CC=C1 ZURUZYHEEMDQBU-UHFFFAOYSA-N 0.000 description 3
- BHUYWUDMVCLHND-UHFFFAOYSA-N alpha-Hydroxytriazolam Chemical compound C12=CC(Cl)=CC=C2N2C(CO)=NN=C2CN=C1C1=CC=CC=C1Cl BHUYWUDMVCLHND-UHFFFAOYSA-N 0.000 description 3
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 3
- 229960003099 amcinonide Drugs 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 229960003942 amphotericin b Drugs 0.000 description 3
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 3
- 229940061641 androsterone Drugs 0.000 description 3
- LKYQLAWMNBFNJT-UHFFFAOYSA-N anileridine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 LKYQLAWMNBFNJT-UHFFFAOYSA-N 0.000 description 3
- 229960002512 anileridine Drugs 0.000 description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 229950007556 aranidipine Drugs 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 125000005264 aryl amine group Chemical group 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 229960000396 atropine Drugs 0.000 description 3
- 229960002756 azacitidine Drugs 0.000 description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
- ODFHGIPNGIAMDK-NJBDSQKTSA-N azidocillin Chemical compound C1([C@@H](N=[N+]=[N-])C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 ODFHGIPNGIAMDK-NJBDSQKTSA-N 0.000 description 3
- 229960004328 azidocillin Drugs 0.000 description 3
- 229960004099 azithromycin Drugs 0.000 description 3
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 3
- 239000012964 benzotriazole Substances 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 description 3
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 3
- 229960004361 calcifediol Drugs 0.000 description 3
- 235000020964 calcitriol Nutrition 0.000 description 3
- 239000011612 calcitriol Substances 0.000 description 3
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 3
- 229940095758 cantharidin Drugs 0.000 description 3
- 229930008397 cantharidin Natural products 0.000 description 3
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 3
- 229960000830 captopril Drugs 0.000 description 3
- ZRWWEEVEIOGMMT-UHFFFAOYSA-N carbamazepine-10,11-epoxide Chemical compound NC(=O)N1C2=CC=CC=C2C2OC2C2=CC=CC=C12 ZRWWEEVEIOGMMT-UHFFFAOYSA-N 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 150000001733 carboxylic acid esters Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 description 3
- 229950005984 cerulenin Drugs 0.000 description 3
- 150000001793 charged compounds Chemical class 0.000 description 3
- 238000009388 chemical precipitation Methods 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- 229960002436 cladribine Drugs 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229960002227 clindamycin Drugs 0.000 description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 3
- WRCHFMBCVFFYEQ-UHFFFAOYSA-N clofedanol Chemical compound C=1C=CC=C(Cl)C=1C(O)(CCN(C)C)C1=CC=CC=C1 WRCHFMBCVFFYEQ-UHFFFAOYSA-N 0.000 description 3
- 229960004472 clofedanol Drugs 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 229960004126 codeine Drugs 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000006352 cycloaddition reaction Methods 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- OBATZBGFDSVCJD-UHFFFAOYSA-N de-O-acetyl-lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(O)C1OC1OC(CO)C(O)C(O)C1O OBATZBGFDSVCJD-UHFFFAOYSA-N 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- OBATZBGFDSVCJD-LALPQLPRSA-N deslanoside Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OBATZBGFDSVCJD-LALPQLPRSA-N 0.000 description 3
- 229960001324 deslanoside Drugs 0.000 description 3
- 229960004281 desmopressin Drugs 0.000 description 3
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 3
- 125000000309 desoxyribosyl group Chemical class C1(C[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 230000000368 destabilizing effect Effects 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 3
- 238000006193 diazotization reaction Methods 0.000 description 3
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 3
- 229960000648 digitoxin Drugs 0.000 description 3
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 3
- 229960005156 digoxin Drugs 0.000 description 3
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 3
- LJOQGZACKSYWCH-UHFFFAOYSA-N dihydro quinine Natural products C1=C(OC)C=C2C(C(O)C3CC4CCN3CC4CC)=CC=NC2=C1 LJOQGZACKSYWCH-UHFFFAOYSA-N 0.000 description 3
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 3
- 229960000920 dihydrocodeine Drugs 0.000 description 3
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 3
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 3
- 229960001051 dimercaprol Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229960002563 disulfiram Drugs 0.000 description 3
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 3
- 229960005426 doxepin Drugs 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 238000001077 electron transfer detection Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- QGXBDMJGAMFCBF-LUJOEAJASA-N epiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-LUJOEAJASA-N 0.000 description 3
- 229960001904 epirubicin Drugs 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 3
- IWJBVMJWSPZNJH-UQGZVRACSA-N ethyl glucuronide Chemical compound CCO[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IWJBVMJWSPZNJH-UQGZVRACSA-N 0.000 description 3
- 229960004578 ethylmorphine Drugs 0.000 description 3
- 229960002428 fentanyl Drugs 0.000 description 3
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 3
- 229960000961 floxuridine Drugs 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 125000001153 fluoro group Chemical class F* 0.000 description 3
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 3
- 229960000308 fosfomycin Drugs 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 3
- 229950006836 fursultiamine Drugs 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 3
- 229940045883 glutathione disulfide Drugs 0.000 description 3
- IXYVBZOSGGJWCW-UHFFFAOYSA-N glycinexylidide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN IXYVBZOSGGJWCW-UHFFFAOYSA-N 0.000 description 3
- 125000005179 haloacetyl group Chemical group 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 3
- 229960000811 hydroquinidine Drugs 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 3
- 150000003949 imides Chemical group 0.000 description 3
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 3
- 229960004801 imipramine Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 229960001317 isoprenaline Drugs 0.000 description 3
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 3
- 229950011455 isoxepac Drugs 0.000 description 3
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 3
- 229960004144 josamycin Drugs 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 3
- 229960000511 lactulose Drugs 0.000 description 3
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 3
- 229960001848 lamotrigine Drugs 0.000 description 3
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 3
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 description 3
- 108010024409 linaclotide Proteins 0.000 description 3
- 229960000812 linaclotide Drugs 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 3
- 235000019136 lipoic acid Nutrition 0.000 description 3
- 229960004391 lorazepam Drugs 0.000 description 3
- DNVPQKQSNYMLRS-YAPGYIAOSA-N lumisterol Chemical compound C1[C@@H](O)CC[C@@]2(C)[C@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-YAPGYIAOSA-N 0.000 description 3
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- NNCAWEWCFVZOGF-UHFFFAOYSA-N mepiquat Chemical compound C[N+]1(C)CCCCC1 NNCAWEWCFVZOGF-UHFFFAOYSA-N 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 229960002330 methocarbamol Drugs 0.000 description 3
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 3
- SYHGEUNFJIGTRX-UHFFFAOYSA-N methylenedioxypyrovalerone Chemical compound C=1C=C2OCOC2=CC=1C(=O)C(CCC)N1CCCC1 SYHGEUNFJIGTRX-UHFFFAOYSA-N 0.000 description 3
- 229960001383 methylscopolamine Drugs 0.000 description 3
- 229960000554 metrizamide Drugs 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- 229960000282 metronidazole Drugs 0.000 description 3
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 3
- 229960003128 mupirocin Drugs 0.000 description 3
- 229930187697 mupirocin Natural products 0.000 description 3
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 3
- 229960003255 natamycin Drugs 0.000 description 3
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 3
- 239000004311 natamycin Substances 0.000 description 3
- 235000010298 natamycin Nutrition 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 3
- IKACRWYHQXOSGM-UTKZUKDTSA-N norpropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CNC)C=1C=CC=CC=1)C1=CC=CC=C1 IKACRWYHQXOSGM-UTKZUKDTSA-N 0.000 description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- VQOXZBDYSJBXMA-RKEBNKJGSA-N nystatin a1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@@H]1OC1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)C[C@](O)(CC(O)C2C(O)=O)OC2C1 VQOXZBDYSJBXMA-RKEBNKJGSA-N 0.000 description 3
- 229960002700 octreotide Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 3
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 3
- 229960004535 oxazepam Drugs 0.000 description 3
- 229960005118 oxymorphone Drugs 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 3
- 229960001914 paromomycin Drugs 0.000 description 3
- 108010083444 peginesatide Proteins 0.000 description 3
- 229960004772 peginesatide Drugs 0.000 description 3
- 229960001639 penicillamine Drugs 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229960000482 pethidine Drugs 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical group O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 238000006303 photolysis reaction Methods 0.000 description 3
- 229960003171 plicamycin Drugs 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 229960000249 pregnenolone Drugs 0.000 description 3
- OZZAYJQNMKMUSD-DMISRAGPSA-N pregnenolone succinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 OZZAYJQNMKMUSD-DMISRAGPSA-N 0.000 description 3
- 150000003138 primary alcohols Chemical class 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 239000012521 purified sample Substances 0.000 description 3
- FKGBIZLRHZTCCL-UHFFFAOYSA-N pyridine-4-carboxylic acid 2,2,2-trifluoroacetic acid Chemical compound FC(C(=O)O)(F)F.C(C1=CC=NC=C1)(=O)O FKGBIZLRHZTCCL-UHFFFAOYSA-N 0.000 description 3
- 229960003581 pyridoxal Drugs 0.000 description 3
- 235000008164 pyridoxal Nutrition 0.000 description 3
- 239000011674 pyridoxal Substances 0.000 description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- 229960001404 quinidine Drugs 0.000 description 3
- LZPZPHGJDAGEJZ-AKAIJSEGSA-N regadenoson Chemical compound C1=C(C(=O)NC)C=NN1C1=NC(N)=C(N=CN2[C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=N1 LZPZPHGJDAGEJZ-AKAIJSEGSA-N 0.000 description 3
- 229960003614 regadenoson Drugs 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 229940099204 ritalin Drugs 0.000 description 3
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 3
- 229960004617 sapropterin Drugs 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 3
- 229960002646 scopolamine Drugs 0.000 description 3
- 150000003333 secondary alcohols Chemical class 0.000 description 3
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 3
- 229960005265 selenium sulfide Drugs 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 229940014800 succinic anhydride Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000003871 sulfonates Chemical class 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 3
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 3
- 229960004907 tacalcitol Drugs 0.000 description 3
- 229960000235 temsirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 3
- 150000003509 tertiary alcohols Chemical class 0.000 description 3
- 150000003515 testosterones Chemical class 0.000 description 3
- AUZONCFQVSMFAP-UHFFFAOYSA-N tetraethylthiuram disulfide Natural products CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 3
- 229960000278 theophylline Drugs 0.000 description 3
- 229960002663 thioctic acid Drugs 0.000 description 3
- 229960004402 tiopronin Drugs 0.000 description 3
- SRPWOOOHEPICQU-UHFFFAOYSA-N trimellitic anhydride Chemical compound OC(=O)C1=CC=C2C(=O)OC(=O)C2=C1 SRPWOOOHEPICQU-UHFFFAOYSA-N 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 3
- 229960002431 trimipramine Drugs 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 3
- 229960000604 valproic acid Drugs 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 3
- 229960001028 zanamivir Drugs 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- 229960002555 zidovudine Drugs 0.000 description 3
- RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 2
- CTAPFRYPJLPFDF-HQMMCQRPSA-N 1,2-oxazole Chemical group C1=CON=[14CH]1 CTAPFRYPJLPFDF-HQMMCQRPSA-N 0.000 description 2
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical group C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 description 2
- DAGFSGJPCQWLPB-UHFFFAOYSA-O 2-[1-[(2-methyltetrazol-5-yl)methyl]pyridin-1-ium-3-yl]acetohydrazide Chemical compound CN1N=C(N=N1)C[N+]1=CC(=CC=C1)CC(=O)NN DAGFSGJPCQWLPB-UHFFFAOYSA-O 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001211 electron capture detection Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- VSEROABGEVRIRY-UHFFFAOYSA-N 1-(chloromethyl)benzotriazole Chemical compound C1=CC=C2N(CCl)N=NC2=C1 VSEROABGEVRIRY-UHFFFAOYSA-N 0.000 description 1
- NAOPGVBLRHCPHI-UHFFFAOYSA-N 2-(chloromethyl)-1,3-oxazole Chemical compound ClCC1=NC=CO1 NAOPGVBLRHCPHI-UHFFFAOYSA-N 0.000 description 1
- MSFVEEFXECBJPG-UHFFFAOYSA-N 2-(chloromethyl)pyrimidine Chemical compound ClCC1=NC=CC=N1 MSFVEEFXECBJPG-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OMXYXOIKYRALRC-UHFFFAOYSA-N 5-(chloromethyl)-1-methylimidazole;hydrochloride Chemical compound Cl.CN1C=NC=C1CCl OMXYXOIKYRALRC-UHFFFAOYSA-N 0.000 description 1
- YGFXNNJIVZUYCL-UHFFFAOYSA-N 5-(chloromethyl)-2-methyltetrazole Chemical compound CN1N=NC(CCl)=N1 YGFXNNJIVZUYCL-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UDCDYIGDQUBUHQ-UHFFFAOYSA-N C1=CC(=C[N+](=C1)CC2=NC=CO2)CC(=O)N[NH3+].C(=O)(C(F)(F)F)[O-].C(=O)(C(F)(F)F)[O-] Chemical compound C1=CC(=C[N+](=C1)CC2=NC=CO2)CC(=O)N[NH3+].C(=O)(C(F)(F)F)[O-].C(=O)(C(F)(F)F)[O-] UDCDYIGDQUBUHQ-UHFFFAOYSA-N 0.000 description 1
- PRVUBJDKDZAJKH-UHFFFAOYSA-N C1=CC=C2C(=C1)N=NN2C[N+]3=CC=CC(=C3)CC(=O)N[NH3+].C(=O)(C(F)(F)F)[O-].C(=O)(C(F)(F)F)[O-] Chemical compound C1=CC=C2C(=C1)N=NN2C[N+]3=CC=CC(=C3)CC(=O)N[NH3+].C(=O)(C(F)(F)F)[O-].C(=O)(C(F)(F)F)[O-] PRVUBJDKDZAJKH-UHFFFAOYSA-N 0.000 description 1
- BZURZBUHUIOZNM-NYNUMMRSSA-O C=C(CC(CN)=O)/C=C\C=[NH+]\Cc1ncccn1 Chemical compound C=C(CC(CN)=O)/C=C\C=[NH+]\Cc1ncccn1 BZURZBUHUIOZNM-NYNUMMRSSA-O 0.000 description 1
- WSZXXAPEZDDPRS-UHFFFAOYSA-N CN1C=NC=C1C[N+]2=CC=CC(=C2)CC(=O)N[NH3+].C(=O)(C(F)(F)F)[O-].C(=O)(C(F)(F)F)[O-] Chemical compound CN1C=NC=C1C[N+]2=CC=CC(=C2)CC(=O)N[NH3+].C(=O)(C(F)(F)F)[O-].C(=O)(C(F)(F)F)[O-] WSZXXAPEZDDPRS-UHFFFAOYSA-N 0.000 description 1
- JMKZVXRIFLFLKR-UHFFFAOYSA-N CN1N=C(c(cc2)ccc2[N](C)(C)CCCON)N=C=C1 Chemical compound CN1N=C(c(cc2)ccc2[N](C)(C)CCCON)N=C=C1 JMKZVXRIFLFLKR-UHFFFAOYSA-N 0.000 description 1
- PYAQTQXFMQWCHQ-UHFFFAOYSA-O C[n]1c(C[NH3+])cnc1 Chemical compound C[n]1c(C[NH3+])cnc1 PYAQTQXFMQWCHQ-UHFFFAOYSA-O 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 1
- 229960004991 artesunate Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 238000000766 differential mobility spectroscopy Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000005597 hydrazone group Chemical group 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- GAPYKZAARZMMGP-UHFFFAOYSA-N pyridin-1-ium;acetate Chemical compound CC(O)=O.C1=CC=NC=C1 GAPYKZAARZMMGP-UHFFFAOYSA-N 0.000 description 1
- WMIRUJZSQZXRCG-UHFFFAOYSA-N pyridine-3-carboxylic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CN=C1 WMIRUJZSQZXRCG-UHFFFAOYSA-N 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Xは、分析物分子と共有結合を形成することができる反応性基であり、
L1及びL2は、互いに独立した置換リンカ又は非置換リンカ、特に線形リンカであり、
Yは、ニュートラル・ロス・ユニットであり、
Zは、少なくとも1つの永久荷電部分を含む荷電ユニットであり、
その任意の塩を含む。
(a)分析物分子を本発明の第1の態様の式Aの化合物と反応させることにより、分析物分子と本発明の第1の態様の式Aの化合物との共有結合付加物を形成する工程、及び
(b)工程(a)からの該付加物を質量分光分析に供する工程。
単語「含む(comprise)」、並びに「含む(comprises)」及び「含むこと(comprising)」のような変形は、記載された整数若しくは工程又は整数若しくは工程のグループの包含を意味するが、いかなる他の整数若しくは工程又は整数若しくは工程のグループの除外をも意味しないことが理解されるであろう。
第1の態様では、本発明は、式A:
Xは、反応性ユニットであり、
L1及びL2は、互いに独立した置換リンカ又は非置換リンカ、特に線形リンカであり、
Yは、ニュートラル・ロス・ユニットであり、
Zは、特に1つの永久荷電部分を含む、少なくとも1つの永久荷電部分を含む荷電ユニットであり、
その任意の塩を含む。
(i)ヒドラジンユニット、例えばH2N−NH−又はH2N−NR1−ユニット(式中、R1は、アリール、1つ以上のヘテロ原子を含むアリール、又はC1〜4アルキル、特にC1又はC2アルキルであり、場合により例えば、ハロ、ヒドロキシル、及び/又はC1〜3アルコキシで置換されている)と、
(ii)ヒドラジドユニット、特にカルボヒドラジド又はスルホヒドラジドユニット、特にH2N−NH−C(O)−又はH2N−NR2−C(O)−ユニット(式中、R2は、アリール、1つ以上のヘテロ原子を含むアリール、又はC1〜4アルキル、特にC1又はC2アルキルであり、場合により例えば、ハロ、ヒドロキシル、及び/又はC1〜3アルコキシで置換されている)と、
(iii)ヒドロキシルアミノユニット、例えばH2N−O−ユニットと、
(iv)ジチオールユニット、特に1,2−ジチオール又は1,3−ジチオールユニットと、から選択される。
(i)ヒドラジンユニット、例えばH2N−NH−又はH2N−NR1−ユニット(式中、R1は、アリール、1つ以上のヘテロ原子を含むアリール、又はC1〜4アルキル、特にC1又はC2アルキルであり、場合により例えば、ハロ、ヒドロキシル、及び/又はC1〜3アルコキシで置換されている)と、
(ii)ヒドラジドユニット、特にカルボヒドラジド又はスルホヒドラジドユニット、特にH2N−NH−C(O)−又はH2N−NR2−C(O)−ユニット(式中、R2は、アリール、1つ以上のヘテロ原子を含むアリール、又はC1〜4アルキル、特にC1又はC2アルキルであり、場合により例えば、ハロ、ヒドロキシル、及び/又はC1〜3アルコキシで置換されている)と、
(iii)ヒドロキシルアミノユニット、例えばH2N−O−ユニットと、から選択される。
(i)少なくとも1つの正電荷部分、
又は
(ii)少なくとも1つの負電荷部分を含むか、又はこれからなる。
(iii)標識3
Tは、分析物(anlyte)分子であり、
X’は、式Aの化合物の反応性ユニットXと分析物分子Tとの反応から生じる部分であり、
L1及びL2は、互いに独立した置換リンカ又は非置換リンカ、特に線形リンカであり、
Yは、ニュートラル・ロス・ユニットであり、
Zは、少なくとも1つの永久荷電部分、特に、1つの永久荷電部分を含む、荷電ユニットであり、
その任意の塩を含む。
(i)ヒドラジンユニット、例えばH2N−NH−又はH2N−NR1−ユニット(式中、R1は、アリール、1つ以上のヘテロ原子を含むアリール、又はC1〜4アルキル、特にC1又はC2アルキルであり、場合により例えば、ハロ、ヒドロキシル、及び/又はC1〜3アルコキシで置換されている)と、
(ii)ヒドラジドユニット、特にカルボヒドラジド又はスルホヒドラジドユニット、特にH2N−NH−C(O)−又はH2N−NR2−C(O)−ユニット(式中、R2は、アリール、1つ以上のヘテロ原子を含むアリール、又はC1〜4アルキル、特にC1又はC2アルキルであり、場合により例えば、ハロ、ヒドロキシル、及び/又はC1〜3アルコキシで置換されている)と、
(iii)ヒドロキシルアミノユニット、例えばH2N−O−ユニットと、
(iv)ジチオールユニット、特に1,2−ジチオール又は1,3−ジチオールユニットと、から選択される。
(i)ヒドラジンユニット、例えばH2N−NH−又はH2N−NR1−ユニット(式中、R1は、アリール、1つ以上のヘテロ原子を含むアリール、又はC1〜4アルキル、特にC1又はC2アルキルであり、場合により例えば、ハロ、ヒドロキシル、及び/又はC1〜3アルコキシで置換されている)と、
(ii)ヒドラジドユニット、特にカルボヒドラジド又はスルホヒドラジドユニット、特にH2N−NH−C(O)−又はH2N−NR2−C(O)−ユニット(式中、R2は、アリール、1つ以上のヘテロ原子を含むアリール、又はC1〜4アルキル、特にC1又はC2アルキルであり、場合により例えば、ハロ、ヒドロキシル、及び/又はC1〜3アルコキシで置換されている)と、
(iii)ヒドロキシルアミノユニット、例えばH2N−O−ユニットと、から選択される。
(i)少なくとも1つの正電荷部分、
又は
(ii)少なくとも1つの負電荷部分を含むか、又はこれからなる。
Xは、反応性ユニットであり、
L1及びL2は、互いに独立した置換リンカ又は非置換リンカ、特に線形リンカであり、
Yは、ニュートラル・ロス・ユニットであり、
Zは、少なくとも1つの永久荷電部分、特に、1つの永久荷電部分を含む、荷電ユニットであり、
その任意の塩を含むか、
又は、式Aの少なくとも1つの化合物を含む、組成物若しくはキットの、
分析物分子の質量分析測定用の使用であって、式中、該質量分析測定が、特にタンデム質量分析測定、より具体的には三段四重極装置を含む。
(i)ヒドラジンユニット、例えばH2N−NH−又はH2N−NR1−ユニット(式中、R1は、アリール、1つ以上のヘテロ原子を含むアリール、又はC1〜4アルキル、特にC1又はC2アルキルであり、場合により例えば、ハロ、ヒドロキシル、及び/又はC1〜3アルコキシで置換されている)と、
(ii)ヒドラジドユニット、特にカルボヒドラジド又はスルホヒドラジドユニット、特にH2N−NH−C(O)−又はH2N−NR2−C(O)−ユニット(式中、R2は、アリール、1つ以上のヘテロ原子を含むアリール、又はC1〜4アルキル、特にC1又はC2アルキルであり、場合により例えば、ハロ、ヒドロキシル、及び/又はC1〜3アルコキシで置換されている)と、
(iii)ヒドロキシルアミノユニット、例えばH2N−O−ユニットと、
(iv)ジチオールユニット、特に1,2−ジチオール又は1,3−ジチオールユニットと、から選択される。
(i)ヒドラジンユニット、例えばH2N−NH−又はH2N−NR1−ユニット(式中、R1は、アリール、1つ以上のヘテロ原子を含むアリール、又はC1〜4アルキル、特にC1又はC2アルキルであり、場合により例えば、ハロ、ヒドロキシル、及び/又はC1〜3アルコキシで置換されている)と、
(ii)ヒドラジドユニット、特にカルボヒドラジド又はスルホヒドラジドユニット、特にH2N−NH−C(O)−又はH2N−NR2−C(O)−ユニット(式中、R2は、アリール、1つ以上のヘテロ原子を含むアリール、又はC1〜4アルキル、特にC1又はC2アルキルであり、場合により例えば、ハロ、ヒドロキシル、及び/又はC1〜3アルコキシで置換されている)と、
(iii)ヒドロキシルアミノユニット、例えばH2N−O−ユニットと、から選択される。
(i)少なくとも1つの正電荷部分、
又は
(ii)少なくとも1つの負電荷部分を含むか、又はこれからなる。
(iii)標識3
(a)分析物分子を、本発明の第1の態様に関して本明細書の上記で開示したような式Aの化合物と反応させることにより、分析物分子と式Aの化合物との共有結合付加物を形成する工程、及び
(b)工程(a)の該付加物を質量分光分析に供する工程。
(i)該付加物のイオンを質量分光分析の第1段階に供することによって、該付加物の該親イオンが、その質量/電荷(m/z)比に従って特徴付けられる工程と、
(ii)該付加親イオンのフラグメンテーションを引き起こすことによって、第1の中性成分が放出され、かつ該付加物の娘イオンが生成され、ここで、該付加物の該娘イオンは付加親イオンとそのm/z比が異なる、工程と、
(iii)該付加物の該娘イオンを質量分光分析の第2段階に供することによって、該付加物の該娘イオンがそのm/z比に従って特徴付けられる工程と、を含み、並びに/又は、
ここで、(ii)は、該付加イオンの代替的なフラグメンテーションを更に含み得、それにより、該第1の中性成分とは異なる第2の中性成分が放出され、かつ該付加物の第2の娘イオンが生成され、及び、
ここで、(iii)は、該付加物の該第1及び第2の娘イオンを質量分光分析の第2段階に供することを更に含み得、それにより、該付加物の該第1及び第2の娘イオンが、それらのm/z比に従って特徴付けられる。
1.式Aの化合物:
Xは、特に分析物分子と共有結合を形成することができる、反応性ユニットであり、
L1及びL2は、互いに独立した置換リンカ又は非置換リンカ、特に線形リンカであり、
Yは、ニュートラル・ロス・ユニットであり、
Zは、特に1つの永久荷電部分を含む、少なくとも1つの永久荷電部分を含む荷電ユニットであり、
その任意の塩を含む。
(i)ヒドラジンユニット、特にH2N−NH−又はH2N−NR1−ユニット(式中、R1はアリール又はC1〜4アルキル、特にC1又はC2アルキルであり、任意に置換される)と、
(ii)ヒドラジドユニット、特にカルボヒドラジド又はスルホヒドラジド、特にH2N−NH−C(O)−又はH2N−NR2−C(O)−ユニット(式中、R2は、アリール又はC1〜4アルキル、特にC1又はC2アルキルであり、任意に置換される)と、
(iii)ヒドロキシルアミノユニット、特にH2N−O−ユニットと、
(iv)ジチオールユニット、特に1,2−ジチオール又は1,3−ジチオールユニットと、からなる群から選択される、態様1〜2のいずれか一項に記載の化合物。
Xは、特に分析物分子と共有結合を形成することができる、反応性ユニットであり、
L1及びL2は、互いに独立した(indepependently)置換リンカ又は非置換リンカ、特に線形リンカであり、
Yは、ニュートラル・ロス・ユニットであり、
Zは、特に1つの永久荷電部分を含む、少なくとも1つの永久荷電部分を含む荷電ユニットであり、
その任意の塩を含む化合物の、
又は、式Aの少なくとも1つの化合物を含む、組成物若しくはキットの、
分析物分子の質量分析測定用の使用であって、式中、該質量分析測定が、特にタンデム質量分析測定、より具体的には三段四重極装置を含む。
(a)該分析物分子を、態様1〜9のいずれか一項で定義される式Aの化合物と反応させることによって、分析物分子と該式Aの化合物との共有結合付加物が形成される工程と、
(b)工程(a)からの該付加物を質量分光分析に供する工程と、を含み、
好ましくは、ここで、該質量分光分析工程(b)は:
(i)該付加物のイオンを質量分光分析の第1段階に供することによって、該付加物の該イオンが、その質量/電荷(m/z)比に従って特徴付けられる工程と、
(ii)該付加イオンのフラグメンテーションを引き起こすことによって、第1の中性成分、特に低分子量の中性成分が放出され、かつ該付加物の娘イオンが生成され、ここで、該付加物の該娘イオンは付加イオンとそのm/z比が異なる、工程と、
(iii)該付加物の該娘イオンを質量分光分析の第2段階に供することによって、該付加物の該娘イオンがそのm/z比に従って特徴付けられる工程と、を含み、並びに/又は、
ここで、(ii)は、該付加イオンの代替的なフラグメンテーションを更に含み得、それにより、該第1の中性成分とは異なる第2の中性成分が放出され、かつ該付加物の第2の娘イオンが生成され、及び、
ここで、(iii)は、該付加物の該第1及び第2の娘イオンを質量分光分析の第2段階に供することを更に含み得、それにより、該付加物の該第1及び第2の娘イオンが、それらのm/z比に従って特徴付けられる。
1.工程:2−[1−[(2−メチルテトラゾール−5−イル)メチル]ピリジン−1−イウム−3−イル]アセトヒドラジド;2,2,2−トリフルオロアセテート;2,2,2−トリフルオロ酢酸の合成:
0分:98%H2O 0.1%TFA、2%CH3CN 0.1%TFA;
0〜10分:98%H2O 0.1%TFA、2%CH3CN 0.1%TFA;
10〜60分:70%H2O 0.1%TFA、30%CH3CN 0.1%TFA;
60〜90分:20%H2O 0.1%TFA、80%CH3CN 0.1%TFA;
1H NMR(400MHz,DMSO−d6)δppm3.69(s,2H)4.36(s,3H)6.26(s,2H)8.05−8.23(m,1H)8.53−8.64(m,1H)9.04−9.17(m,2H).
13C NMR(101MHz,DMSO−d6)δppm37.29(1C)40.33(1C)54.82(1C)128.19(1C)137.65(1C)144.50(1C)145.72(1C)148.58(1C)160.48(1C)167.50(1C).
HPLC−MS(m/z)[M]+計算値248.1259 検出値248.33
0分:H2O中95%25mM NH4COO、CH3CN/H2O中5%25mM NH4COO(80:20);
0〜40分:H2O中0%25mM NH4COO、CH3CN/H2O中100%25mM NH4COO(80:20);
1H NMR(400MHz,DMSO−d6)δppm3.65(s,3H)4.08(s,2H)6.00−6.11(m,2H)7.49−7.58(m,1H)7.59−7.69(m,2H)7.84−7.92(m,2H)8.16−8.27(m,1H)8.36(s,4H)8.57−8.66(m,1H)9.00−9.08(m,2H)9.15−9.21(m,1H).
HPLC−MS(m/z)[M]+計算値309.13515 検出値309.2
0分:95%H2O 1%HCOOH、5%CH3CN 1%HCOOH;
0〜35分:20%H2O 1%HCOOH、80%CH3CN 1%HCOOH;
1H NMR(400MHz,MeOD−d4)δppm3.74−3.84(m,2H)6.02−6.11(m,2H)7.49−7.57(m,1H)7.57−7.65(m,2H)7.82−7.88(m,2H)8.08−8.15(m,1H)8.52−8.55(m,1H)8.55−8.58(m,2H)8.76−8.81(m,1H)9.05−9.10(m,1H)9.13(s,1H).
HPLC−MS(m/z)[M]+計算値309.14638 検出値309.2
0分:100%H2O 0.1%TFA、0%CH3CN 0.1%TFA;
0〜80分:20%H2O 0.1%TFA、80%CH3CN 0.1%TFA;
80〜85分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
85〜93分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
93〜96分:60%H2O 0.1%TFA、40%CH3CN 0.1%TFA;
96〜99分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
99〜100分60%H2O 0.1%TFA;40%CH3CN 0.1%TFA.
1H NMR(400MHz、メタノールL−d4)δppm4.05(s,3H)6.14(s,2H)7.50−7.54(m,1H)7.55−7.66(m,2H)7.77−7.88(m,2H)8.58(d,J=6.65Hz,2H)8.77(s,1H)9.33(d,J=6.90Hz,2H).
13C NMR(101MHz、メタノール−d4)δppm53.04(1C)55.67(1C)120.28(2C)123.43(1C)127.50(2C)129.14(1C)129.65(2C)136.62(1C)140.04(1C)145.51(1C)146.16(2C)162.05(1C).
HPLC−MS(m/z)[M]+計算値295.11950 検出値295.45.
0分:100%H2O 0.1%TFA、0%CH3CN 0.1%TFA;
0〜60分:50%H2O 0.1%TFA;50%CH3CN 0.1%TFA;
60〜64分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
64〜80分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
80〜83分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
83〜89分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
89〜90分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA.
1H NMR(400MHz、メタノール−d4)δppm6.12(s,2H)7.48−7.56(m,1H)7.56−7.64(m,2H)7.81−7.86(m,2H)8.43(d,J=6.90Hz,2H)8.78(s,1H)9.29(d,J=6.97Hz2H).
13C NMR(101MHz、メタノール−d4)δppm55.43(1C)120.28(2C)123.42(1C)125.96(2C)129.12(1C)129.64(2C)136.63(1C)140.14(1C)145.80(2C)148.44(1C)161.53(1C).
HPLC−MS(m/z)[M]+計算値295.13073 検出値295.11.
0分:100%H2O 0.1%TFA、0%CH3CN 0.1%TFA;
0〜60分:50%H2O 0.1%TFA;50%CH3CN 0.1%TFA;
60〜64分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
64〜80分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
80〜83分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
83〜89分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
89〜90分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA.
HPLC−MS(m/z)[M]+計算値295.11950 検出値295.38.
0分:100%H2O 0.1%TFA、0%CH3CN 0.1%TFA;
0〜60分:50%H2O 0.1%TFA;50%CH3CN 0.1%TFA;
60〜64分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
64〜80分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
80〜83分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
83〜89分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
89〜90分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA.
1H NMR(400MHz、メタノール−d4)δppm6.14(s,2H)7.49−7.54(m,1H)7.56−7.61(m,2H)7.81−7.85(m,2H)8.24−8.28(m,1H)8.79(s,1H)8.94−8.96(m,1H)9.29−9.31(m,1H)9.60(s,1H).
13C NMR(101MHz、メタノール−d4)δppm55.75(1C)120.28(2C)123.43(1C)128.27(1C)129.12(1C)129.63(2C)133.37(1C)136.62(1C)140.12(1C)143.93(1C)144.66(1C)146.71(1C)161.30(1C)
HPLC−MS(m/z)[M]+計算値295.13073 検出値295.11.
0分:100%H2O 0.1%TFA、0%CH3CN 0.1%TFA;
0〜60分:50%H2O 0.1%TFA;50%CH3CN 0.1%TFA;
60〜64分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
64〜72分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
72〜74分:40%H2O 0.1%TFA;60%CH3CN 0.1%TFA;
74〜79分:40%H2O 0.1%TFA;60%CH3CN 0.1%TFA;
79〜80分:40%H2O 0.1%TFA;60%CH3CN 0.1%TFA.
1H NMR(400MHz、メタノール−d4)δppm3.75(s,3H)3.91(s,3H)4.05(s,2H)6.14(s,2H)7.91(s,1H)8.15(dd,J=7.97,6.21Hz,1H)8.63(d,J=8.03Hz,1H)8.95−9.07(m,2H)9.11(s,1H).
13C NMR(101MHz、メタノール−d4)δppm32.99(1C)36.14(1C)51.71(1C)52.28(1C)122.98(1C)126.59(1C)127.99(1C)136.95(1C)138.29(1C)143.08(1C)145.22(1C)148.02(1C)170.03(1C).
HPLC−MS(m/z)[M]+計算値246.12425 検出値246.39.
0分:100%H2O 0.1%TFA、0%CH3CN 0.1%TFA;
0〜60分:70%H2O 0.1%TFA;30%CH3CN 0.1%TFA;
60〜64分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
64〜80分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
80〜83分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
83〜89分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
89〜90分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA.
1H NMR(400MHz、メタノール−d4)δppm3.91(s,3H)6.13(s,2H)7.90(d,J=1.51Hz,1H)8.14(dd,J=8.03,6.15Hz,1H)8.61(d,J=8.03Hz,1H)8.99−9.02(m,2H)9.11(s,1H).
13C NMR(101MHz、メタノール−d4)δppm32.97(1C)35.62(1C)52.30(1C)123.04(1C)126.56(1C)128.02(1C)136.85(1C)138.32(1C)143.08(1C)145.19(1C)147.75(1C)168.05(1C).
HPLC−MS(m/z)[M]+計算値246.13549 検出値246.23.
0分:100%H2O 0.1%TFA、0%CH3CN 0.1%TFA;
0〜60分:50%H2O 0.1%TFA;50%CH3CN 0.1%TFA;
60〜64分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
64〜80分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
80〜83分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
83〜89分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
89〜90分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA.
1H NMR(400MHz、メタノール−d4)δppm3.75(s,3H)4.07(s,2H)6.15(s,2H)7.46−7.49(m,1H)8.14−8.19(m,1H)8.67(d,J=8.03Hz,1H)8.77−8.79(m,2H)9.03−9.05(m,1H)9.11(s,1H).
13C NMR(101MHz、メタノール−d4)δppm36.26(1C)51.71(1C)64.74(1C)120.89(1C)127.26(1C)136.16(1C)144.70(1C)146.59(1C)147.54(1C)157.87(2C)162.29(1C)169.93(1C).
HPLC−MS(m/z)[M]+計算値244.10860 検出値244.39.
0分:100%H2O 0.1%TFA、0%CH3CN 0.1%TFA;
0〜20分:50%H2O 0.1%TFA;50%CH3CN 0.1%TFA;
20〜24分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
24〜30分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
30〜33分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
33〜39分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
39〜40分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA.
1H NMR(400MHz、メタノール−d4)δppm3.85−3.99(m,2H)6.10−6.12(m,2H)7.45(ss,J=4.96,4.96Hz,1H)8.14(dd,J=8.03,6.15Hz,1H)8.63(dddd,J=8.02,6.54,1.38,1.38Hz,1H)8.76(dd,J=5.02,1.13Hz,2H)8.99−9.02(m,1H)9.07(m,1H).
13C NMR(101MHz、メタノール−d4)δppm36.22(1C)64.44(1C)120.87(1C)127.18(1C)136.62(1C)144.53(1C)146.39(1C)147.28(1C)157.83(2C)162.22(1C)169.56(1C).
HPLC−MS(m/z)[M]+計算値244.11984 検出値244.39.
0分:100%H2O 0.1%TFA、0%CH3CN 0.1%TFA;
0〜60分:30%H2O 0.1%TFA;70%CH3CN 0.1%TFA;
60〜64分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
64〜80分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
80〜83分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
83〜89分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
89〜90分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA.
1H NMR(400MHz、メタノール−d4)δppm3.74(s,3H)4.05(s,2H)6.11(s,2H)7.23(s,1H)8.03(d,J=0.75Hz,1H)8.17(dd,J=8.03,6.15Hz,1H)8.66(d,J=8.16Hz,1H)9.07(d,J=6.15Hz,1H)9.15(s,1H).
13C NMR(101MHz、メタノール−d4)δppm36.22(1C)51.71(1C)56.34(1C)127.64(1C)127.74(1C)136.73(1C)141.61(1C)143.96(1C)145.95(1C)148.13(1C)156.55(1C)169.81(1C).
HPLC−MS(m/z)[M]+計算値233.09262 検出値233.36.
0分:100%H2O 0.1%TFA、0%CH3CN 0.1%TFA;
0〜40分:90%H2O 0.1%TFA、10%CH3CN 0.1%TFA;
40〜44分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
44〜50分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
50〜53分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
53〜59分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
59〜60分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA.
1H NMR(400MHz、アセトニトリル−d3)δppm3.76(s,2H)5.89(s,2H)7.20(d,J=0.75Hz,1H)7.93(d,J=0.88Hz,1H)8.04(dd,J=8.09,6.21Hz,1H)8.55(dd,J=8.28,1.38Hz,1H)8.77(dd,J=6.24,1.21Hz,1H)8.96(s,1H).
13C NMR(101MHz、アセトニトリル−d3)δppm36.49(1C)56.66(1C)127.85(1C)128.01(1C)137.73(1C)141.66(1C)143.54(1C)145.53(1C)147.91(1C)156.09(1C)167.63(1C).
HPLC−MS(m/z)[M]+計算値233.10385 検出値232.70.
0分:100%H2O 0.1%TFA、0%CH3CN 0.1%TFA;
0〜60分:50%H2O 0.1%TFA;50%CH3CN 0.1%TFA;
60〜64分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
64〜80分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
80〜83分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
83〜89分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
89〜90分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA.
1H NMR(400MHz、メタノール−d4)δppm3.70(s,3H)4.04(s,2H)7.52(dd,J=7.68,7.68Hz,1H)7.59(s,2H)7.70(dd,J=7.73,7.73Hz,1H)8.04−8.08(m,2H)8.16(dd,J=7.97,6.34Hz,1H)8.64(d,J=8.03Hz,1H)9.22(d,J=6.15Hz,1H)9.33(s,1H).
13C NMR(101MHz、メタノール−d4)δppm36.17(1C)51.69(1C)68.18(1C)109.40(1C)119.65(1C)125.31(1C)128.08(1C)129.39(1C)132.60(1C)137.13(1C)142.57(1C)144.66(1C)145.87(1C)149.18(1C)169.75(1C).
HPLC−MS(m/z)[M]+計算値283.11950 検出値283.41.
0分:100%H2O 0.1%TFA、0%CH3CN 0.1%TFA;
0〜40分:90%H2O 0.1%TFA、10%CH3CN 0.1%TFA;
40〜44分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
44〜50分:2%H2O 0.1%TFA;98%CH3CN 0.1%TFA;
50〜53分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
53〜59分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA;
59〜60分:60%H2O 0.1%TFA;40%CH3CN 0.1%TFA.
13C NMR(101MHz、アセトニトリル−d3)δppm36.37(1C)68.38(1C)109.78(1C)120.13(1C)125.34(1C)128.22(1C)129.42(1C)132.89(1C)137.94(1C)142.30(1C)144.04(1C)146.07(1C)148.98(1C)167.53(1C).
テストステロンの500ng/mL溶液(S1)をメタノールで調製した。メタノール(モル比>1000)中で希釈した、溶液(S1)と比べて誘導体化試薬標識1、2、8、13、及び14のいずれかを過剰に含む溶液(S2)を加え、溶液を氷酸性酸(glacial acidic acid)(20%v/v)で酸性化した。溶液S1及びS2を混合して溶液S3を得て、65℃で2時間保持し、続いて室温で12時間保持した。12時間後、溶液S3をメタノールで希釈して、1等量テストステロンのテストステロンの分子量;1/20等量のテストステロン;1/40等量のテストステロン;1/100等量のテストステロン、及び1/200等量のテストステロンに基づく5つの独立した濃度レベルを得た。1等量は検出器の比例領域内であり、1/200等量のテストステロンは使用する機器の検出限界を下回るように選択される。例として、Waters Quattro microシステムには以下の濃度が使用されている(100ng/mL;5ng/mL;2,5ng/mL;1ng/mL;500pg/ml)。溶液S2を用いて、ブランク溶液0ng/mLを調製した。
・極性 ES+
・較正 静的2
・キャピラリ(kV)3.00 3.00
・コーン(V)50.00 53.36
・抽出器(V)3.00 3.54
・RFレンズ(V)0.2 0.2
・ソース温度(℃)140 138
・脱溶媒和温度(℃)350 348
・コーンガス流量(L/時)50 49
・脱溶媒和ガス流量(L/時)650 646
・LM1解像度 5.0
・HM1解像度 15.0
・イオンエネルギー1 1.0
・入口 50−65
・衝突 2−15
・出口 50−65
・LM2解像度 5.0
・HM2解像度 15.0
・イオンエネルギー2 1.0
・増倍器(V)650−647
・シリンジポンプ流量(uL/分)40.0
・ガス・セル・ピラニ圧(mbar)1.87e−4
・機器パラメータ−機能2:
・極性 ES+
・較正 静的2
・キャピラリ(kV)3.00 3.00
・コーン(V)50.00 53.36
・抽出器(V)3.00 3.54
・RFレンズ(V)0.2 0.2
・ソース温度(℃)140 138
・脱溶媒和温度(℃)350 348
・コーンガス流量(L/時)50 49
・脱溶媒和ガス流量(L/時)650 646
・LM1解像度 5.0
・HM1解像度 15.0
・イオンエネルギー1 1.0
・入口 50−65
・衝突 2−15
・出口 50−65
・LM2解像度 5.0
・HM2解像度 15.0
・イオンエネルギー2 1.0
・増倍器(V)650−647
・シリンジポンプ流量(uL/分)40.0
・ガス・セル・ピラニ圧(mbar)1.87e−4
・機器パラメータ−機能3:
・極性 ES+
・較正 静的2
・キャピラリ(kV)3.00 3.00
・コーン(V)50.00 53.36
・抽出器(V)3.00 3.54
・RFレンズ(V)0.2 0.2
・ソース温度(℃)140 138
・脱溶媒和温度(℃)350 348
・コーンガス流量(L/時)50 49
・脱溶媒和ガス流量(L/時)650 646
・LM1解像度 5.0
・HM1解像度 15.0
・イオンエネルギー1 1.0
・入口 50−65
・衝突 2−15
・出口 50−65
・LM2解像度 5.0
・HM2解像度 15.0
・イオンエネルギー2 1.0
・増倍器(V)650−647
・シリンジポンプ流量(uL/分)40.0
・ガス・セル・ピラニ圧(mbar)1.87e−4
・ACE実験記録
・−−−−−−−−−メソッドパラメータ実行−−−−−−−−−
・Waters ACQUITY SDS
・実施時間:10.00分
・コメント:
・溶媒選択A:A1
・溶媒選択B:B1
・低圧限界:0.000bar
・高圧限界:1034.200bar
・溶媒名A:水
・溶媒名B:アセトニトリル
・スイッチ1:変更せず
・スイッチ2:オン
・スイッチ3:変更せず
・シールウォッシュ:5.0分
・チャートアウト1:システム圧力
・チャートアウト2:%B
・システム圧力データチャネル:はい
・流量データチャネル:いいえ
・%Aデータチャネル:いいえ
・%Bデータチャネル:いいえ
・プライマリA圧力データチャネル:いいえ
・アキュムレータA圧力データチャネル:いいえ
・プライマリB圧力データチャネル:いいえ
・アキュムレータB圧力データチャネル:いいえ
・デガッサ圧力データチャネル:いいえ
・[勾配テーブル]
・時間(分)流量 %A %B 曲線
・1.開始時 0.400 98.0 2.0
・2.7.00 0.400 20.0 80.0 6
・3.7.10 0.400 0.0 100.0 6
・4.8.00 0.400 0.0 100.0 6
・5.8.10 0.400 98.0 2.0 6
・6.10.00 0.400 98.0 2.0 6
・イベント実行:はい
・[イベントテーブル]
・実行時間(分)イベント操作 パラメータ
・1.0.10 スイッチ2オン 0.00
・2.3.50 スイッチ2オフ 0.00
・3.9.00 スイッチ2オン 0.00
・
・Waters 996 PDA
・開始波長(nm)210.00
・終了波長(nm)400.00
・解像度(nm)1.2
・サンプリングレート(スペクトル/秒)2.000
・フィルタ応答 1
・露出時間(ミリ秒)自動
・内挿 656 はい
・取込停止時間(分)10.00
・ディスクに保存:はい
・Waters 996 PDAアナログチャネル1
・出力モード オフ
・Waters 996 PDAアナログチャネル2
・出力モード オフ
・
・Waters ACQUITYオートサンプラ
・実施時間:10.00分
・コメント:
・事前ロード:無効
・ループオプション:ニードルオーバーフィルを用いたパーシャルループ
・LoopOffline:無効
・弱洗浄溶媒名:メタノール
・弱洗浄量:600uL
・強洗浄溶媒名:メタノール
・強洗浄量:200uL
・目標カラム温度:40.0℃
・カラム温度アラームバンド:20.0℃
・目標試料温度:10.0℃
・試料温度アラームバンド:10℃
・フル・ループ・オーバーフィル要素:自動
・シリンジ引出速度:自動
・ニードル配置:自動
・吸引前エアギャップ:自動
・吸引後エアギャップ:自動
・カラム温度データチャネル:はい
・周囲温度データチャネル:はい
・試料温度データチャネル:いいえ
・試料オーガナイザ温度データチャネル:いいえ
・試料圧力データチャネル:いいえ
・スイッチ1:変更せず
・スイッチ2:オン
・スイッチ3:変更せず
・スイッチ4:変更せず
・チャートアウト:試料圧力
・試料温度アラーム:有効
・カラム温度アラーム:有効
・イベント実行:はい
・[イベントテーブル]
・実行時(分)イベント操作
・1.0.10 スイッチ2オン
・2.3.00 スイッチ2オフ
・3.3.10 スイッチ2トグル
・4.8.00 スイッチ2パルス
・5.8.10 スイッチ2オフ
・6.10.00 スイッチ2オン
・ニードルオーバーフィルフラッシュ:自動
・試料分析注入パラメータ
注入量(uL)−10.00
Claims (14)
- 前記反応性ユニットXが、カルボニル反応性ユニット、ジエン反応性ユニット、ヒドロキシル反応性ユニット、アミノ反応性ユニット、イミン反応性ユニット、チオール反応性ユニット、ジオール反応性ユニット、フェノール反応性ユニット、エポキシド反応性ユニット、ジスルフィド反応性ユニット、及びアジド反応性ユニットからなる群から選択される、請求項1に記載の化合物。
- 前記反応性ユニットXが、カルボニル反応性基であり、特に式中、Xが、
(i)ヒドラジンユニット、特にH2N−NH−又はH2N−NR1−ユニット(式中、R1はアリール又はC1〜4アルキル、特にC1又はC2アルキルであり、任意に置換される)と、
(ii)ヒドラジドユニット、特にカルボヒドラジド又はスルホヒドラジド、特にH2N−NH−C(O)−又はH2N−NR2−C(O)−ユニット(式中、R2は、アリール又はC1〜4アルキル、特にC1又はC2アルキルであり、任意に置換される)と、
(iii)ヒドロキシルアミノ−ユニット、特にH2N−O−ユニットと、
(iv)ジチオールユニット、特に1,2−ジチオール又は1,3−ジチオールユニット、
からなる群から選択される、請求項1又は2に記載の化合物。 - 前記反応性ユニットXが、チオール反応性基であるか、又はN−ヒドロキシスクシンイミド(NHS)エステル若しくはスルホ−NHSエステル、ヒドロキシベンゾトリアゾール(HOBt)エステル、又は1−ヒドロキシ−7−アカベンゾトリアゾール(HOAt)エステル基といった、活性エステル基などのアミノ反応性基である、請求項1又は2に記載の化合物。
- 前記ニュートラル・ロス・ユニットYが、イオン化の際に中性成分を放出する、請求項1〜4のいずれか一項に記載の化合物。
- 前記荷電ユニットZが、永久荷電している、請求項1〜5のいずれか一項に記載の化合物。
- 前記リンカL1 L2が、互いに独立して、1〜10個のC原子を含み、任意に1個以上のヘテロ原子を含む、請求項1〜6のいずれか一項に記載の化合物。
- 前記反応性ユニットXがカルボニル反応性基であり、前記ニュートラル・ロス・ユニットYが5員ヘテロ環部分であり、前記電荷ユニットZが1つの永久的に正に荷電した部分を含む、請求項1〜7のいずれか一項に記載の化合物。
- 前記反応性ユニットXがH2N−NH−であり、前記ニュートラル・ロス・ユニットYがトリアゾール又はテトラゾールであり、前記電荷ユニットZがピペリジンユニットを含む、請求項1〜8のいずれか一項に記載の化合物。
- 請求項1〜9のいずれか一項に記載の化合物を含む、組成物。
- 請求項1〜9のいずれか一項に化合物、又は請求項10に記載の組成物を含む、キット。
- 互いに共有結合した分析物分子と請求項1〜9のいずれか一項に記載の化合物とを含む共有結合付加物であって、特に、前記共有結合付加物が、前記分析物分子と請求項1〜9のいずれかの化合物との化学反応によって形成される、共有結合付加物。
- 式A:
Xは、特に分析物分子と共有結合を形成することができる、反応性ユニットであり、
L1及びL2は、互いに独立した(indepependently)置換リンカ又は非置換リンカ、特に線形リンカであり、
Yは、ニュートラル・ロス・ユニットであり、
Zは、特に1つの永久荷電部分を含む、少なくとも1つの永久荷電部分を含む荷電ユニットであり、
及びその任意の塩を含む、化合物の、
又は、式Aの少なくとも1つの化合物を含む、組成物若しくはキットの、
分析物分子の質量分析測定用の使用であって、式中、前記質量分析測定が、特にタンデム質量分析測定、より具体的には三段四重極装置を含む、使用。 - 分析物分子の質量分析測定のための方法であって、以下の工程:
(a)前記分析物分子を、請求項1〜9のいずれか一項で定義される式Aの化合物と反応させることによって、分析物分子と前記式Aの化合物との共有結合付加物が形成される工程と、
(b)工程(a)からの前記付加物を質量分光分析に供する工程と、を含み、
好ましくは、ここで、前記質量分光分析工程(b)は:
(i)前記付加物のイオンを質量分光分析の第1段階に供することによって、前記付加物の前記イオンが、その質量/電荷(m/z)比に従って特徴付けられる工程と、
(ii)前記付加イオンのフラグメンテーションを引き起こすことによって、第1の中性成分、特に低分子量の中性成分が放出され、かつ前記付加物の娘イオンが生成され、ここで、前記付加物の前記娘イオンは付加イオンとそのm/z比が異なる工程と、
(iii)前記付加物の前記娘イオンを質量分光分析の第2段階に供することによって、前記付加物の前記娘イオンがそのm/z比に従って特徴付けらる工程と、を含み、並びに/又は、
ここで、(ii)は、前記付加物イオンの代替的なフラグメンテーションを更に含み得、それにより、前記第1の中性成分とは異なる第2の中性成分が放出され、かつ前記付加物の第2の娘イオンが生成され、及び、
ここで、(iii)は、前記付加物の前記第1及び第2の娘イオンを質量分光分析の第2段階に供することを更に含み得、それにより、前記付加物の前記第1及び第2の娘イオンが、それらのm/z比に従って特徴付けられる、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18185355 | 2018-07-24 | ||
EP18185355.7 | 2018-07-24 | ||
PCT/EP2019/069730 WO2020020850A1 (en) | 2018-07-24 | 2019-07-23 | Reagent for mass spectrometry |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021532118A true JP2021532118A (ja) | 2021-11-25 |
Family
ID=63079747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021503727A Pending JP2021532118A (ja) | 2018-07-24 | 2019-07-23 | 質量分析のための試薬 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11885818B2 (ja) |
EP (1) | EP3826995A1 (ja) |
JP (1) | JP2021532118A (ja) |
KR (1) | KR20210035813A (ja) |
CN (1) | CN112492881A (ja) |
BR (1) | BR112021001006A2 (ja) |
WO (1) | WO2020020850A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021234003A1 (en) * | 2020-05-20 | 2021-11-25 | F. Hoffmann-La Roche Ag | Benzylpyridinium reagent for mass spectrometry |
CN115667223A (zh) * | 2020-05-20 | 2023-01-31 | 豪夫迈·罗氏有限公司 | 质谱用咪唑鎓试剂 |
JP2023546477A (ja) * | 2020-10-22 | 2023-11-02 | エフ. ホフマン-ラ ロシュ アーゲー | ナノesi質量分析法による目的の分析物の検出 |
EP4267951A1 (en) * | 2020-12-22 | 2023-11-01 | F. Hoffmann-La Roche AG | Automated clinical diagnostic system and method |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7556969B2 (en) * | 2002-12-19 | 2009-07-07 | Northeastern University | Intensified neutral loss tags and use thereof in mass spectrometry |
WO2004070352A2 (en) * | 2003-01-30 | 2004-08-19 | Applera Corporation | Methods, mixtures, kits and compositions pertaining to analyte determination |
JP2004317398A (ja) * | 2003-04-18 | 2004-11-11 | Amersham Bioscience Kk Kk | 質量分析法 |
US20110003395A1 (en) * | 2009-05-31 | 2011-01-06 | Dh Technologies Development Pte. Ltd. | Specific analysis of analytes using reagent compounds, labeling strategies, and mass spectrometry workflow |
WO2011059457A1 (en) | 2009-11-16 | 2011-05-19 | University Of Notre Dame Du Lac | High performance luminescent compounds |
EP2528443B1 (en) | 2010-01-25 | 2017-01-11 | DH Technologies Development Pte. Ltd. | Quantitative analysis of vitamin d3, vitamin d2, and metabolites thereof |
WO2013108113A1 (en) * | 2012-01-20 | 2013-07-25 | Dh Technologies Development Pte. Ltd. | Analysis of estradiol and analytes with phenolic oh using labeling chemistry and lc-msms workflow |
EP2664821A1 (de) | 2012-05-16 | 2013-11-20 | IMO Holding GmbH | Vorrichtung zur verdrehbaren Kopplung zweier Baugruppen |
GB201215924D0 (en) * | 2012-09-06 | 2012-10-24 | Univ Swansea | Kit and method for quantitative detection of steroids |
GB201308765D0 (en) * | 2013-05-15 | 2013-06-26 | Electrophoretics Ltd | Mass Tag Reagents |
KR20190109448A (ko) * | 2017-01-31 | 2019-09-25 | 에프. 호프만-라 로슈 아게 | 질량 분광분석을 위한 시약 |
KR20210035814A (ko) * | 2018-07-24 | 2021-04-01 | 에프. 호프만-라 로슈 아게 | 질량 분석법용 시약 |
KR20210035812A (ko) * | 2018-07-24 | 2021-04-01 | 에프. 호프만-라 로슈 아게 | 질량 분석법용 시약 |
CN115667223A (zh) * | 2020-05-20 | 2023-01-31 | 豪夫迈·罗氏有限公司 | 质谱用咪唑鎓试剂 |
WO2021234003A1 (en) * | 2020-05-20 | 2021-11-25 | F. Hoffmann-La Roche Ag | Benzylpyridinium reagent for mass spectrometry |
CN116710783A (zh) * | 2020-12-03 | 2023-09-05 | 豪夫迈·罗氏有限公司 | 通过交叉喷雾esi质谱检测目标分析物 |
-
2019
- 2019-07-23 JP JP2021503727A patent/JP2021532118A/ja active Pending
- 2019-07-23 EP EP19742602.6A patent/EP3826995A1/en active Pending
- 2019-07-23 WO PCT/EP2019/069730 patent/WO2020020850A1/en unknown
- 2019-07-23 BR BR112021001006-8A patent/BR112021001006A2/pt not_active Application Discontinuation
- 2019-07-23 CN CN201980048604.4A patent/CN112492881A/zh active Pending
- 2019-07-23 KR KR1020217002338A patent/KR20210035813A/ko unknown
-
2021
- 2021-01-21 US US17/155,054 patent/US11885818B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3826995A1 (en) | 2021-06-02 |
BR112021001006A2 (pt) | 2021-04-20 |
CN112492881A (zh) | 2021-03-12 |
WO2020020850A1 (en) | 2020-01-30 |
US11885818B2 (en) | 2024-01-30 |
KR20210035813A (ko) | 2021-04-01 |
US20210140983A1 (en) | 2021-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11845733B2 (en) | Reagent for mass spectrometry | |
US11885818B2 (en) | Reagent for mass spectrometry | |
US20230127289A1 (en) | Benzylpyridinium reagent for mass spectrometry | |
US20230314444A1 (en) | Detection of an analyte of interest by cross spray esi mass spectrometry | |
US20230160904A1 (en) | Reagent for mass spectrometry | |
US20230104200A1 (en) | Imidazolium reagent for mass spectrometry | |
US20210188788A1 (en) | Reagent for mass spectrometry | |
US20230324398A1 (en) | Reagent for mass spectrometry | |
US20230333113A1 (en) | Detection of an analyte of interest by nanoesi mass spectrometry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220708 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230705 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230725 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231025 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240119 |